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Highlights	
• Fibrinogen	falls	before	other	coagulation	factors	during	postpartum	haemorrhage	(PPH)	
• Laboratory	Clauss	fibrinogen	and	point	of	care	Fibtem	A5®	predict	progression	of	PPH	
• Haemostatic	impairment	is	uncommon	during	PPH	and	can	be	assessed	by	Fibtem		
• A	fibrinogen	of	2	g/L	or	Fibtem	A5	12	mm	and	above	is	adequate	for	haemostasis	during	PPH	
• A	national	quality	improvement	programme	has	been	initiated	integrating	these	results		
	
Summary	
Postpartum	haemorrhage	(PPH)	is	caused	by	obstetric	complications	but	may	be	exacerbated	by	
haemostatic	impairment.	In	a	ten	year	programme	of	research	we	have	established	that	haemostatic	
impairment	is	uncommon	in	moderate	PPH	and	that	fibrinogen	falls	earlier	than	other	coagulation	
factors.	Laboratory	Clauss	fibrinogen	and	the	point	of	care	surrogate	measure	of	fibrinogen	(Fibtem®	
A5	measured	on	the	Rotem®	machine)	are	predictive	biomarkers	for	progression	from	early	to	severe	
PPH,	the	need	for	blood	transfusion	and	invasive	procedures	to	control	haemorrhage.	Fibrinogen	
replacement	is	not	required	in	PPH	unless	the	plasma	level	falls	below	2	g/L	or	the	Fibtem	A5	is	
2	
	
below	12mm.	Deficiencies	of	coagulation	factors	other	than	fibrinogen	are	uncommon	even	during	
severe	PPH,	and	Rotem	monitoring	can	inform	withholding	FFP	safely	in	most	women.	In	the	
absence	of	placental	abruption,	clinically	significant	thrombocytopenia	is	uncommon	unless	the	
platelet	count	is	low	before	the	bleed	started,	or	very	large	bleeds	(>5000	mL)	occur.	Measuring	
blood	loss	is	feasible	in	routine	practice	during	PPH	and	is	more	accurate	than	estimation.	These	
research	findings	have	been	collated	to	design	an	ongoing	quality	improvement	programme	for	all	
maternity	units	in	Wales	called	OBS	Cymru	(Wales)	(The	Obstetric	Bleeding	Strategy	for	Wales)	.		
	
Aims	
The	aims	of	this	review	are	to:	Summarise	the	literature	relating	to	the	coagulation	profile	of	women	
with	PPH,	describe	how	point	of	care	(POC)	based	algorithms	can	provide	timely	information	for	
clinicians	with	the	potential	to	reduce	blood	product	use	and	describe	how	protocols	used	during	
research	can	have	a	positive	impact	on	all	patients	with	fewer	major	complications	and	massive	
blood	transfusions.	
	
Background	
The	incidence	of	postpartum	haemorrhage	(PPH)	is	increasing	in	many	countries	and	is	the	most	
common	cause	of	death	for	women	of	child	bearing	age	worldwide.
1-6
	Blee	
ding	is	caused	by	obstetric	complications	but	may	be	exacerbated	by	haemostatic	impairment.
7
	It	is	
widely	assumed	that	haemostatic	impairment	often	complicates	PPH	and	consequently,	when	
coagulation	test	results	are	unavailable,	guidelines	endorse	the	use	of	formulaic	infusion	of	fresh	
frozen	plasma	(FFP)	or	cryoprecipitate	in	fixed	ratios	with	red	blood	cells	(RBC),
8-10
	based	on	
evidence	extrapolated	from	non-pregnant	adult	major	trauma.		It	is	questionable	whether	these	
data	should	be	applied	to	the	management	of	PPH	given	the	very	different	baseline	coagulation	
status	of	the	groups.		
High	quality	studies	describing	coagulopathies	associated	with	PPH	are	limited,	however	it	is	
probably	that	they	result	from	complex	interactions	between	dilution,	local	consumption,	
disseminated	consumption	and	increased	fibrinolysis.
7
	The	nature	of	haemostatic	impairment	varies	
according	to	the	cause	of	the	bleed	and	is	affected	by	complications	of	pregnancy	such	as	pre-
eclampsia,	sepsis	and	impaired	liver	function.	The	physiological	adaptions	of	pregnancy	result	in	a	
pro-thrombotic	state	at	term	with	increased	levels	of	pro-coagulants	and	decreased	anti-coagulants.	
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In	particular,	at	term	the	fibrinogen	level	is	4-6	g/L	at	term	gestation,		compared	to	2-4	g/L	in	healthy	
non-pregnant	women.
11;12
	Until	recently	it	was	not	known	whether	fibrinogen	replacement	during	
severe	PPH	should	target	‘normal	for	term’	(>4	g/L),	‘normal	for	the	non-pregnancy’	(>2	g/L),	or	
somewhere	in	between.		This	is	important	when	considering	the	role	of	FFP	in	treating	coagulopathy	
in	PPH.
13
	
FFP	contains	about	2	g/L	of	fibrinogen,	whereas	the	average	fibrinogen	level	in	a	woman	with	1000-
2000	ml	blood	loss	due	to	atony	or	trauma	is	about	4	g/L.
14
	This	means	that	in	most	cases,	infusion	
of	FFP	during	PPH	would	reduce	fibrinogen	by	dilution.
15
	This	implies	that	unmonitored	fixed-ratio	
infusions	of	FFP	would	expose	many	women	to	FFP	without	any	prospect	of	improving	haemostasis.	
Studies	exploring	the	use	of	fixed-ratio	infusions	of	FFP:RBC	during	PPH	report	fewer	women	
developing	laboratory	evidence	of	coagulopathy,	however,	some	of	these	studies	describe	multiple	
interventions	including	early	involvement	of	senior	staff.
16-20
	When	guided	by	viscoelastometric	point	
of	care	testing	(VE-POCT),	we	have	shown	that	FFP	can	be	withheld	safely	in	women	experiencing	
moderate	to	severe	PPH,	without	development	of	clinical	significant	haemostatic	impairment.
21
	A	
recent	review	suggested	that	FFP	was	not	the	optimal	way	to	replace	fibrinogen	during	PPH.
13
	
	
PPH	Observations	and	Research	Advancements	in	Cardiff,	Wales	
Using	Fibrinogen	Concentrate	to	Treat	PPH	with	Hypofibrinogenemia	
We	observed	that	some	women	experiencing	severe	PPH	had	laboratory	fibrinogen	levels	<1	g/L	
associated	with	clinical	haemostatic	impairment.	At	this	time	the	Royal	College	of	Obstetrics	and	
Gynaecology	(RCOG)	guidance	was	to	maintain	fibrinogen	>1	g/L	using	cryoprecipitate.
22
	Thawing	
and	infusing	cryoprecipitate	takes	time,	delaying	correction	of	the	coagulopathy.	At	our	centre	and	
others,	we	addressed	this	issue	by	infusing	fibrinogen	concentrate	which	rapidly	increased	the	
fibrinogen	level	and	was	associated	with	the	clinical	impression	of	improvement	in	haemostasis.
23-26
	
We	infused	fibrinogen	concentrate	between	2	and	4	G	to	six	women	over	a	2-year	period	
(approximately	12,000	deliveries)	with	clinical	improvement,	although	the	data	on	all	women	with	
low	fibrinogen	was	not	collected	at	this	time
24
	These	early	reports	reflected	a	reactive	rather	than	
preventative	strategy	to	haemostatic	impairment.	More	recent	studies	from	other	groups	have	
reported	improvements	in	haemostasis	with	the	use	of	fibrinogen	concentrate	to	treat	
hypofibrinogenaemia.
27;28
	These	case	reports	are	selective	and	prone	to	reporting	bias,	but	were	
sufficiently	encouraging	to	promote	further	investigation.		
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The	role	of	Standard	Coagulation	Tests	and	Clauss	Fibrinogen	for	Detection	of	Coagulopathy	in	PPH	
To	investigate	the	effect	of	severity	of	bleeding	on	standard	coagulation	tests,	we	evaluated	a	
consecutive	cohort	of	18,501	women	who	delivered	at	our	unit	over	3	years.		Women	with	PPH	
>1500	mL	(n=456,	2.5%)	had	their	blood	test	results	reviewed.	PT	and	aPTT	usually	remained	within	
the	normal	range	until	blood	loss	reached	4000-5000	mL.
29
	This	reflected	sufficient	coagulation	
factors	for	haemostasis	until	the	bleed	volume	reached	4000-	5000	ml,	and	infusion	of	FFP	up	to	that	
time	was	unlikely	to	have	improved	haemostasis.	In	contrast,	fibrinogen	fell	rapidly	as	blood	volume	
loss	increased,	such	that	by	2000	mL	the	majority	of	cases	had	a	fibrinogen	below	the	normal	range	
for	term	(4	g/L),	and	at	4000	mL	most	women	had	a	fibrinogen	<2	g/L.
29
	A	UK	Obstetric	Surveillance	
System		(UKOSS)	survey	of	women	transfused	≥8	units	of	RBC	(average	blood	loss	6000	mL)	also	
found	that	many	more	women	had	a	fibrinogen	<2	g/L	than	an	abnormal	PT	or	aPTT	both	at	first	
presentation	and	when	coagulation	was	at	its	worst.
30
	The	likelihood	of	hypofibrinogenaemia	
depended	on	the	cause	of	bleeding	and	was	most	often	associated	with	placental	abruption.
14;30
	
Taken	together,	these	studies	indicate	that	the	standard	coagulation	tests	PT	and	aPTT		show	that	
early	depletion	of	coagulation	factors	is	uncommon		in	obstetric	haemorrhage,	and	that	plasma	
fibrinogen	level	may	be	a	more	important	therapeutic	target.	
	
Fibrinogen	and	Fibtem	as	biomarkers	to	predict	severity	of	progression	of	postpartum	haemorrhage	
In	an	influential	paper,	Charbit	et	al	measured	multiple	coagulation	factors	in	women	experiencing	
PPH.	Fibrinogen	level	was	the	only	independent	predictor	of	progression	to	severe	PPH	and	a	
fibrinogen	<2	g/L	had	had	a	100%	positive	predictive	value	for	progression	from	moderate	to	severe	
PPH.
31
	This	finding	has	been	confirmed	by	us	in	retrospective	and	prospective	studies	and	by	other	
groups	investigating	PPH	in	multiple	cohorts	using	diverse	methodologies	(Table	1).
14;31-35
	These	
studies	now	show	convincingly	that	plasma	Clauss	fibrinogen,	measured	early	during	PPH,	is	a	
biomarker	for	predicting	progression	to	severe	PPH.		
Although	plasma	Clauss	fibrinogen	levels	yields	useful	information,	it	takes	at	least	an	hour	for	a	
result	to	be	available,	limiting	its	utility	to	direct	practice	during	PPH.	VE-POCTs	generate	a	surrogate	
measure	of	fibrinogen	with	results	available	within	10	minutes	of	venipuncture.
36-38
	We	initiated	the	
Obstetric	Bleeding	Study	1	(OBS-1)	to	investigate	whether	a	Fibtem®	assay,	performed	on	the	Rotem®	
machine	(Werfen,	Barcelona,	Spain),	could	predict	progression	from	early	to	severe	PPH.	A	
consecutive	cohort	of	346	women	with	PPH	>1000	mL	was	enrolled.	At	recruitment	baseline	Fibtem	
was	performed	concurrently	with	a	plasma	Clauss	fibrinogen,	whilst	all	other	routine	PPH	
5	
	
management	was	provided.		Clinicians	were	blinded	to	the	Fibtem	result	but	did	know	the	
laboratory	fibrinogen	when	it	became	available	(Fig.	1).
14
		
Despite	only	a	moderate	correlation	between	Clauss	fibrinogen	and	Fibtem	(r=0.59)	the	two	
parameters	had	an	almost	identical	value	for	predicting	progression.	As	the	Clauss	fibrinogen	or	
Fibtem	fell	the	need	for	any	RBC	transfusion,	≥4	units	RBC,	≥8	units	of	blood	products	
(RBC+FFP+platelets),	use	of	an	invasive	procedure	or	a	bleed	>2500	mL	increased.	The	lower	the	
fibrinogen	or	Fibtem	A5	the	higher	the	proportion	of	women	with	poor	outcomes	(Fig.2).	For	
example,	the	median	(IQR)	fibrinogen	and	Fibtem	A5	of	women	who	received	≥8	units	of	blood	
products	was	2.1	(1.8-3.4)	g/L	and	12	(7-17)	mm,	respectively,	compared	with	3.9	(3.2-4.5)and	19	
(17-23)	in	those	who	did	not.	Fibtem	A5	<10	mm	was	associated	with	more	prolonged	bleeding	
(median	127	versus	65	minutes,	p=0.02),	longer	in	level	2	care	(patients	needing	extended	post-
operative	care	with	enhanced	interventions	and	monitoring)	(median	24	versus	11	hours,	p<0.001)	
and	shorter	time	to	first	RBC	transfusion	(p<0.001).	In	addition,	the	combination	of	a	low	
fibrinogen/Fibtem,	with	the	clinical	observation	that	there	was	on-going	PPH	at	recruitment,		was	a	
stronger	predictor	of	these	poor	outcomes	than	either	alone.
14
	
	
OBS-1	confirmed	that	a	low	fibrinogen	or	Fibtem	A5,	measured	early	during	a	PPH	was	associated	
with	progression	of	PPH,	however	it	remained	unknown	whether	correction	of	these	parameters	
would	improve	outcome.	Furthermore,	the	appropriate	clinical	target	for	fibrinogen	or	Fibtem	A5	to	
maintain	haemostasis,	and	therefore	when	fibrinogen	containing	products	should	be	infused,	was	
unknown.	
	
Appropriate	Triggers	for	Fibrinogen	replacement	during	PPH	
In	an	audit	report	comparing		a	Rotem-based	algorithm	(that	infused	3g	of	fibrinogen	concentrate	if	
the	Fibtem	was	<7	mm,	or	<12	mm	with	severe	bleeding,	and	FFP	if	the	Extem	CT	was	>100s)	with	
the	Unit’s	previous	practice	of	treating	major	PPH	with	shock	packs	(consisting	of	4	RBC,	4	FFP	and	1	
pool	of	platelets):	The	Rotem-based	algorithm	was	associated	with	a	large	reduction	in	FFP,	
cryoprecipitate	and	platelet	usage,	fewer	women	needed	>5	units	RBC,	or	had	transfusion	
associated	circulatory	overload	or	admission	to	ITU.
39;40
	While	these	data	were	retrospective	and	un-
randomized,	their	outcomes	indicate	that	ROTEM-guided	transfusion	management	may	be	superior	
to	an	empiric	massive	transfusion	approach	for	PPH.	There	is	no	information	in	the	paper	about	
response	times	to	administration	of	blood	products	after	adoption	of	fibrinogen	concentrate	
6	
	
infusions,	although	immediate	availability	of	fibrinogen	concentrate	stored	on	their	delivery	suite	
may	have	reduced	response	time	and	therefore	improved	clinical	outcomes.	
A	prospective,	double-blind,	randomised	controlled	trial	(RCT)	led	by	Wikkelsoe	investigated	
whether	infusing	2g	of	fibrinogen	concentrate	after	500-1000	mL	blood	loss,	irrespective	of	plasma	
fibrinogen	level,	reduced	the	need	for	RBC	transfusion	and	blood	loss.	No	difference	in	outcomes	
was	achieved	with	the	empiric	administration	of	2G	fibrinogen	concentrate	for	PPH	showing	that	
early	pre-emptive,	formulaic	fibrinogen	replacement	was	not	indicated.	Analysis	found	that	the	
average	fibrinogen	level	when	fibrinogen	concentrate	had	been	infusion	was	about	4.5	g/L	in	both	
arms	of	the	study,	demonstrating	that	this	level	is	adequate	for	haemostasis	during	PPH.
41
	The	
results	provide	good	evidence	against	the	use	of	empiric	fibrinogen	replacement	during	PPH	in	the	
absence	of	a	monitored	low	plasma	fibrinogen	level,	while	exposing	many	women	to	plasma-derived	
blood	products	unnecessarily.	
In	the	Obstetric	Bleeding	Study	2	(OBS-2)	we	used	Fibtem	A5	and	observation	of	ongoing	bleeding	to	
guide	fibrinogen	and	FFP	replacement.	In	OBS-1,	a	Fibtem	A5	<16	mm	(fibrinogen	about	3	g/L),	in	a	
woman	with	ongoing	bleeding,	had	been	associated	with	progression	to	multiple	poor	outomes
14
	
and	this	was	supported	by	other	observational	studies	(Table	1).	OBS-2	was	a	double-blind,	placebo	
controlled	RCT	which	enrolled	women	with	PPH	>1000-1500	mL.	The	study	investigated	whether	
infusing	fibrinogen	concentrate
42
	if	Fibtem	A5	was	<16	mm	and	bleeding	was	ongoing	reduced	blood	
product	usage.	OBS-2	also	investigated	whether	it	was	safe	to	withhold	FFP	if	Fibtem	A5
43
	was	≥15	
mm	on	the	assumption	that	a	normal	fibrinogen	was	a	surrogate	for	adequate	levels	of	other	
coagulation	factors	(Fig.3a).
14;29;31
	
There	was	no	statistically	significant	difference	in	any	outcome	between	the	fibrinogen	and	placebo	
(Normal	saline)	groups,	demonstrating	that	a	fibrinogen	of	around	3	g/L	is	adequate	for	haemostasis	
during	PPH.
44
	Pre-specified	subgroup	analyses
43
	showed	that	fibrinogen	>2	g/L	or	Fibtem	A5	>12	mm	
were	adequate	for	haemostasis	despite	severe	PPH.	However,	if	Fibtem	A5	or	fibrinogen	was	<12	
mm	or	<2	g/L	at	the	time	of	randomisation,	women	in	the	fibrinogen	group	received	fewer	blood	
products	and	had	lower	blood	loss	after	study	medication	compared	to	placebo.
44
	These	exploratory	
subgroup	analyses	did	not	reach	statistical	significance	possibly	due	to	the	small	number	of	women	
randomised	with	a	fibrinogen	<2	g/L.	However	these	results,	in	conjunction	with	the	data	from	
Mallaiah
39
,	suggest	that	an	appropriate	intervention	point	for	infusion	of	fibrinogen	is	a	Fibtem	A5	
<12	mm	or	fibrinogen	<2	g/L,	and	a	study	investigating	this	is	warranted.	
In	our	experience	a	fibrinogen	level	below	2	g/L	is	uncommon	during	obstetric	haemorrhage.	
Combining	data	from	consecutive	studies	and	observation	from	our	institution	over	the	last	8	years	
7	
	
shows	a	rate	of	1-2/1000	deliveries	and	a	similar	incidence	has	been	observed	across	all	units	in	
Wales.	In	OBS-2,	irrespective	of	blood	loss,	women	with	a	Fibtem	A5	>15	mm	or	who	had	stopped	
bleeding,	had	FFP	withheld	(n=605).	Median	(IQR)	blood	loss	was	1500	ml	(1300-	2000	ml)	and	none	
of	the	women	developed	haemostatic	impairment
21
	suggesting	that	haemostatic	impairment	during	
PPH	can	be	assessed	accurately	using	VE-POCTs.		
Thrombocytopenia	and	platelet	transfusion	during	postpartum	haemorrhage	
It	has	been	suggested	that	a	massive	transfusion	protocol	used	for	PPH	should	include	
platelets.
18;20;45;46
	Guidelines	recommend	maintaining	the	platelet	count	above	75	x10
9
/L	during	
PPH.
8;9
	There	are	limited	data	on	the	incidence	and	causes	of	thrombocytopenia	during	PPH,	
therefore	we	analysed	the	women	recruited	to	the	OBS-1	study.	In	moderate	to	severe	PPH,	
thrombocytopenia	was	uncommon,	with	8/347	(2.3%)	women	having	a	platelet	count	<75	x10
9
/L.	
Twelve	women	(3.4%)	received	a	platelet	transfusion	and	these	fell	into	two	groups.	Firstly,	women	
who	were	thrombocytopenic	before	delivery	due	to	pre-eclampsia	or	pre-existing	diseases	such	as	
immune	or	inherited	thrombocytopenia	and	secondly,	women	with	initially	normal	platelet	counts	
who		either	had	a	placental	abruption	or	bleeds	>5000	mL.
47
	These	findings	were	supported	by	the	
UKOSS	survey	of	women	who	received	≥8	unit	of	RBC	(median	blood	loss	6000	mL)	where	the	
median	first	platelet	count	taken	during	the	bleed	was	131x10
9
/L	and	lowest	was	68x10
9
/L,	77%	of	
these	women	received	a	platelet	transfusion.	Placental	abruption	was	associated	with	the	largest	fall	
in	platelet	count	(137	to	54	x10
9
/L).
30
	These	reports	suggest	that	the	platelet	count	is	adequate	
during	PPH	in	the	vast	majority	of	cases,	and	inclusion	of	platelets	in	shock	packs	would	result	in	
many	women	receiving	unnecessary	platelet	infusions.		
Measurement	of	blood	loss	after	delivery	and	during	PPH	
Early	recognition	of	PPH	with	measured	rather	than	estimated	blood	loss	is	critical	because	clinicians	
often	underestimate	the	volume	of	bleeding.
48
		Measurement	of	blood	loss	is	more	accurate	and	is	
feasible	in	routine	practice,	should	be	started	after	every	delivery	even	if	the	initial	loss	seems	
normal
49
	and	is	a	key	recommendation	in	RCOG	guidance.
8
	We	adopted	the	practice	of	gravimetric	
measurement	of	blood	loss	on	swabs	and	pads	with	the	addition	of	measured	blood	loss	in	conical	
under	buttock	drapes	and	suction	bottles	during	our	studies	to	standardise	patient	recruitment	and	
ensure	timely	escalation	of	care.	Measurement	of	blood	loss	alone	does	not	lead	to	improved	
outcomes	during	PPH,
50
	but	when	integrated	into	a	pathway	can	aid	escalation	of	care.
20
	In	addition,	
escalation	of	care	also	needs	to	take	into	account	other	factors	such	as	maternal	vital	signs	as	
bleeding	can	be	concealed	and	the	apparent	rate	of	blood	loss,	although	specific	guidance	is	not	
available.	
8	
	
	
Impact	of	Obstetric	Bleeding	Studies	on	practice	and	evolving	quality	improvement	
Between	2013	and	2015	women	recruited	to	OBS-2	followed	the	study	blood	product	algorithm	(Fig	
2a)	and	those	not	recruited	were	treated	using	the	local	major	obstetric	haemorrhage	ROTEM	
algorithm	(Fig	3b).	Since	2010	PPH	outcome	data	has	been	collected	at	our	institution	as	part	of	a	
quality	improvement	initiative.	During	OBS-2,	RBC	usage	decreased	by	32%,	FFP	usage	by	86%	and	
the	number	of	women	receiving	5	or	more	units	RBC	fell	by	86%	(Fig	4).	In	addition,	bleeds	≥2500	ml	
fell	by	83%	and	level	3	ITU	admissions	(women	requiring	advanced	respiratory	support)	due	to	PPH	
decreased	from	about	4/year	to	none	in	3	years	(Fig	4).	Although	temporally	related,	it	is	unlikely	
that	the	intervention	of	fibrinogen	administration	was	solely	responsible	for	these	improved	
outcomes	as	only	7	women	treated	in	the	interventional	arm	had	a	fibrinogen	<2	g/L.	This	implies	
that	other	factors	associated	with	running	the	study	and	complying	with	protocols	were	influencing	
maternal	outcomes.	In	order	to	standardise	recruitment	to	the	study,	women	were	risk	assessed,	
blood	loss	was	measured	rather	than	estimated	and	obstetricians	and	anaesthetists	attended	the	
mother’s	bedside	to	obtain	consent	and	take	study	bloods	as	specified	in	the	study	protocol.	
When	OBS-2	ended	in	November	2015,	it	was	expected	that	improved	outcomes	would	continue.	
However,	it	rapidly	became	apparent	that	this	was	not	the	case	and	the	end	of	the	study	coincided	
with	an	increase	in	large	haemorrhages	to	rates	similar	to	before	the	study	(Fig	4).	A	systematic	
review	of	16	large	bleeds	over	a	6	month	period	identified	common	themes	including	a	return	to	
estimating	blood	loss,	the	multidisciplinary	team	not	attending	the	mother’s	bedside	in	a	timely	
fashion	and	POCTs	not	being	performed	early	in	the	course	of	the	haemorrhage.	This	resulted	in	
delayed	recognition	of	a	deteriorating	patient	and	delayed	escalation	of	obstetric	intervention.		
	
Quality	improvement	initiatives	in	postpartum	haemorrhage	
	
In	2011	Shields	described	a	quality	improvement	programme	that	standardised	care	during	PPH.	This	
included	risk	assessment	followed	by	an	escalating	3-stage	approach	based	on	500,	1000	and	1500	
mL	blood	loss	and/or	clinical	signs.	This	stepwise,	prescriptive	approach	required	accurate	
contemporaneous	measurement	rather	than	estimation	of	blood	loss	and	was	initiated	after	every	
delivery.	The	protocol	stipulated	that	a	senior	midwife,	obstetrician	and	anaesthetist	should	attend	
the	mother’s	bedside	when	blood	loss	reached	1000	mL.	At	1500	mL	blood	loss,	empirical	fixed-ratio	
blood	product	transfusion	was	started	based	on	data	derived	from	trauma	studies.	The	group	noted	
that	PPH	progressed	in	fewer	women,	the	number	of	blood	products	used	fell	and	fewer	women	
9	
	
developed	coagulopathy.
19
	The	protocol	was	rolled	out	across	a	region	by	the	California	Maternal	
Quality	Care	Collaborative	(CMQCC)	with	similar	results.
20
	A	similar	quality	improvement	programme	
was	initiated	by	The	Association	of	Women’s	Health,	Obstetric	and	Neonatal	Nurses	(AWHONN).	
Both	CMQCC	and	AWHONN	have	extensive	information	available	on	their	websites	
(http://www.awhonn.org/?page=PPHandhttps://www.cmqcc.org/resources-tool-kits/toolkits/ob-
hemorrhage-toolkit).		
	
These	initiatives	overlapped	with	our	experiences	in	terms	of	risk	assessment,	measured	blood	loss	
and	early	escalation	of	obstetric	care	by	senior	clinicians.	The	main	difference	was	the	approach	to	
blood	product	replacement,	liberal	fixed-ratio	infusion	of	blood	products	based	on	data	derived	from	
trauma
19;20
	versus	VE-POCTs	to	target	haemostatic	therapy	based	on	our	programme	of	research.		It	
is	not	known	which	of	these	approaches	results	in	better	outcomes	and	clinical	trials	specifically	
addressing	the	value	of	VE-POCTs	are	required	to	address	this.		
	
Understanding	the	impact	of	point	of	care	tests	of	coagulation	in	postpartum	haemorrhage	
	
During	OBS-2	Rotem-guided	blood	product	replacement	was	introduced	into	routine	practice	at	our	
centre	for	all	patients..	As	experience	increased	and	clinicians	accepted	the	results	as	clinically	
reliable,	management	of	PPH	changed.	If	early	in	the	bleed	the	Rotem	results	were	normal,	the	
bleeding	must	be	due	to	a	physical	cause	(atony,	trauma	or	retained	placental	tissue)	and	not	
coagulopathy.	This	knowledge	facilitated	early	targeted	escalation	of	obstetric	care	and,	if	necessary,	
involvement	of	a	more	experienced	colleague.	If	coagulation	was	abnormal	early	in	the	bleed	the	
mother	was	immediately	identified	as	high	risk.	Early	coagulopathy	in	such	cases	raises	suspicion	of	
delayed	resuscitation,	placental	abruption	or	amniotic	fluid	embolus.	The	mother	required	urgent	
treatment	for	coagulopathy,	almost	always	with	fibrinogen	replacement,	and	escalation	of	obstetric	
management	to	address	the	underlying	cause	of	bleeding.	This	binary	classification	helped	the	team	
focus	on	the	most	important	clinical	problem	and	our	impression	was	that	VE-POCTs	facilitated	
behavioural	change	of	the	multidisciplinary	team.		
	
A	National	Institute	for	Health	and	Care	Excellence	review	of	VE-POCT	during	PPH	focused	only	on	
blood	and	blood	product	usage	(https://www.nice.org.uk/guidance/dg13).		Our	experience	is	that	
VE-POCTs	can	act	as	a	trigger	around	which	care	can	be	structured	by	encouraging	clinicians	to	
attend	the	bedside	early.	The	VE-POCT	results	influence	decision	making	and,	if	normal,	allow	the	
obstetrician	to	focus	on	managing	the	obstetric	cause	of	bleeding	while	the	anaesthetist	
10	
	
concentrates	on	appropriate	resuscitation	and	blood	product	replacement.	Our	observation,	
supported	by	the	findings	from	OBS-2	and	other	retrospective	observational	studies,
27;28;39;40;44
	is	that	
in	the	small	number	of	women	who	are	identified	as	having	a	fibrinogen	<2g/L	or	Fibtem	A5	<12mm,	
rapid	correction	of	hypofibrinogenaemia	with	fibrinogen	concentrate	improves	haemostasis	and	is	
advantageous,	although	large	prospective	trials	are	needed	to	verify	these	findings.			
	
Local	quality	improvement	initiatives	
	
Improved	local	clinical	outcomes	may	be	a	consequence	of	multiple	inter-related	factors.	These	
included	risk	assessment	of	all	women,	cumulative	measurement	of	blood	loss	and	ensuring	that	an	
experienced	midwife,	obstetrician	and	anaesthetist	attend	the	mother	at	1000mL	blood	loss	with	
ROTEM	assessment	of	coagulation	for	all	women	weather	they	were	enrolled	into	the	OBS-2	study	
or	not.	We	do	not	know	which	one	of	these	interventions	improves	outcomes	and	it	is	likely	to	be	a	
combination	of	all	of	these	factors.	Over	a	one	year	period	(2017,	18	months	after	finishing	the	OBS	
2	trial)	in	our	tertiary	referral	centre,	2.8/1000	women	had	a	PPH	>2500mL,	a	blood	transfusion	of	≥5	
units	RBC	or	received	FFP.	When	compared	with	the	published	data	from	Healthcare	Improvement	
Scotland,	where	an	overall	rate	of	6/1000	was	reported,	our	results	fall	below	3	standard	deviations	
from	the	mean.
2
	We	are	currently	seeking	to	replicate	these	improvements	across	Wales.	
	
All	Wales	quality	improvement	programme:	OBS	Cymru	(Obstetric	Bleeding	Strategy	for	Wales	
(Cymru))	
	
OBS	Cymru	(http://www.1000livesplus.wales.nhs.uk/obs-cymru)	is	a	registered	quality	improvement	
initiative	that	aims	to	reduce	maternal	morbidity	due	to	PPH	across	Wales.	Wales	has	a	population	
of	3.1	million	and	delivers	30,000	women	a	year	in12	consultant	led	units	(CLU),	with	between	500-
6000	deliveries	per	annum	in	each	CLU.	The	project	aims	to	reduce	rates	of	major	PPH	and	blood	
transfusion,	level	3	ICU	care	and	hysterectomy	due	to	PPH.	
	
The	OBS	Cymru	intervention	
The	key	to	OBS	Cymru	is	to	limit	the	number	of	moderate	bleeds	that	progress	to	severe	
haemorrhage	and	so	reduce	maternal	morbidity.	The	project	focused	on	4	key	elements	which	draw	
on	the	quality	improvement	work	from	other	groups
19;20
	and	the	lessons	learnt	from	our	research	
programme.		
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1. Risk	assessment	of	all	women:	potential	risk	factors	for	PPH	are	flagged	on	admission	to	
delivery	suite	and	with	on-going	risk	assessment	during	labour.	
2. Cumulative	gravimetric	measurement	of	blood	loss	after	every	delivery:	to	facilitate	
escalation	of	care	with	specific	actions	required	at	500,	1000	and	1500	mL	blood	loss.		
3. Multidisciplinary	care	with	a	senior	midwife,	obstetrician	and	anaesthetist	attending	the	
bedside	at	1000	mL	blood	loss.			
4. Rotem-guided	blood	product	replacement	using	an	algorithm	derived	from	the	results	of	
OBS-2.	
These	themes	are	embedded	into	clinical	practice	using	a	number	of	interventions	and	tools	
(available	at	http://www.1000livesplus.wales.nhs.uk/obs-cymru).	A	PPH	proforma	describing	an	
escalating	4-stage	approach	was	developed	and	is	placed	in	all	mothers’	notes	on	admission	to	
delivery	suite.	(Specific	paperwork	which	describes	all	actions	and	interventions	which	should	occur	
as	PPH	progresses	and	also	acts	as	a	template	for	scribing	the	events).	
• Stage	0:	risk	assessment	for	all	women	in	labour	(on	admission	and	as	labour	progresses).		
• Stage	1:	at	>500mL	after	a	vaginal	birth	a	senior	midwife	is	informed,	the	cause	of	bleeding	
assessed	and	initial	treatment	instituted.		
• Stage	2:	at	>1000mL	a	senior	midwife,	obstetrician	and	anaesthetist	attend	the	bedside	to	
assess	and	escalate	management	as	appropriate.	Samples	for	Rotem,	bedside	lactate	and	
haemoglobin,	FBC	and	coagulation	screen	are	taken	and	tranexamic	acid	is	given.		
• Stage	3:	at	>1500mL	with	on-going	bleeding	the	consultant	obstetrician	and	anaesthetist	are	
informed.	The	major	obstetric	haemorrhage	protocol	is	activated	and	Rotem-guided	blood	
product	replacement	instituted	whilst	medical	and	surgical	treatments	are	continued.	
This	is	a	complex	intervention	and	so	its	impact	is	being	assessed	according	to	Medical	Research	
Council	guidance.
51
	The	step-wise	interventions	have	been	incorporated	into	an	all	Wales	PPH	
guideline	
(http://www.wisdom.wales.nhs.uk/sitesplus/documents/1183/Post%20Partum%20Haemorrhage_M
aternity%20Network%20Wales%20All%20Wales%20Guidelines_2017.pdf)	and	is	based	on	the	Royal	
College	of	Obstetrics	and	Gynaecology	(RCOG)	green-top	guidance
8
and	incorporating	the	OBS	Cymru	
approach.		
Data	are	collected	prospectively	on	all	PPHs	>1000	ml	in	Wales	to	be	compared	with	retrospective	
data	collected	from	the	units.	It	is	too	early	to	assesswhether	key	markers	of	severe	PPH	are	
changing	;	this	information	will	be	reported	at	the	completion	of	the	project	in	2019.		
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OBS	Cymru	Rotem	guided	algorithm	
The	OBS	Cymru	Rotem-guided	blood	product	algorithm	is	shown	in	figure	5		http://www.oaa-
anaes.ac.uk/assets/_managed/cms/files/Guidelines/ROTEM%20Protocol.pdf.		At	1000	mL	blood	loss	
with	ongoing	bleeding	Fibtem	A5	and	Extem	CT,	bedside	venous	lactate	and	haemoglobin	are	
performed	and	FBC	and	coagulation	sent	to	the	laboratory.	Intravenous	tranexamic	acid	is	given.	The	
WOMAN	trial	showed	that	tranexamic	acid,	given	within	3	hours	of	delivery,	reduced	death	due	to	
bleeding	without	an	increase	in	thrombotic	or	other	adverse	events,
52
	our	algorithm	therefore	
infuses	tranexamic	acid	as	soon	as	PPH	is	recognised	or	at	the	latest	1000	mL.	The	rationale	for	early	
Rotem	testing	is	not	only	to	rapidly	identify	the	small	number	of	women	who	need	haemostatic	
support,	but	to	reassure	the	obstetrician	that	coagulation	is	normal	and	focus	treatment	on	obstetric	
causes	of	bleeding.	Haemostatic	blood	product	replacement	initially	focuses	on	fibrinogen.	If	Fibtem	
A5	is	≤12	mm	or	Clauss	fibrinogen	<2	g/L,	fibrinogen	concentrate	is	given.	Fibrinogen	concentrate	is	
not	licensed	for	this	indication	in	the	UK	and	an	alternative,	as	recommended	by	RCOG,	is	to	infuse	
cryoprecipitate.
8
	The	recommendations	on	fibrinogen	replacement	are	based	on	data	from	OBS-2	
and	the	Liverpool	PPH	algorithm.
39;40;44
	The	target	is	to	maintain	the	fibrinogen	>2	g/L	which	is	
supported	in	the	2016	RCOG	guideline.
8;9
If	the	Extem	CT	is	prolonged	above	the	normal	range	(75	
sec	based	on	local	validation)	or	the	PT/aPTT	is	above	the	normal	range,	after	fibrinogen	
replacement,	15	ml/kg	FFP	is	infused	based	on	RCOG	guidance	and	OBS-2	data.
8;44
	Platelets	are	
transfused	if	<75	x10
9
/L	based	on	RCOG	guidance.
8
	Because	coagulopathy	can	evolve	rapidly	during	
PPH	we	repeat	Rotem	and	laboratory	testing	every	500	mL	or	every	30	minutes	during	ongoing	
bleeding,	or	at	any	time	for	clinical	concern.	Tests	are	repeated	after	blood	products	are	given	to	
assess	response.		
The	Future	–	questions	to	be	addressed.	
The	role	of	VE-POCTs	in	the	management	of	PPH	remains	debated
53;54
	and	definitive	evidence	is	
lacking.	We	hypothesise	that	it	is	the	combined	effect	of	the	early	recognition	of	bleeding	triggering	
timely	interventions	incorporating	VE-POCTs	and	a	management	strategy	involving	the	whole	
multidisciplinary	team	that	is	key	to	preventing	progression	of	PPH	and	minimising	morbidity.		A	
study	comparing	such	an	approach	utilising	early	VE-POCT,	with	accepted	standard	care	based	on	
laboratory	tests	of	coagulation	is	now	necessary	although	this	would	necessitate	large	multi-centre	
studies.		It	may	also	be	possible	to	partially	address	some	of	these	questions	by	specifically	studying	
high	risk	surgical	procedures	such	as	women	having	a	Caesarean	section	for	placenta	previa	or	
women	who	present	with	abruption.	
13	
	
Data	on	the	cost	effectiveness	of	such	an	approach	is	important	if	this	is	to	be	used	more	generally	
within	a	variety	of	health	care	settings.	We	suggest	that	qualitative	assessment	of	the	impact	of	the	
intervention	on	team	dynamics	and	behaviour	should	also	be	studied.		A	multinational	group	of	
interested	researchers	may	be	required	to	address	these	issues.	
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Table	1:	
Studies	investigating	the	association	between	fibrinogen	and	progression	of	postpartum	
haemorrhage	
Study	 N	 Study	design	 Fibrinogen	g/L	 	
Time	of	
fibrinogen	assay	
Outcome	defining	
progression	of	
PPH	
Descriptive	
statistic	
reported	
No	
progression	
of	PPH	
Progression	
of	PPH	
ROC	
AUC		
(95%	CI)	
Charbit
31
	 129	 Infusion	of	
uterotonic	after	
manual	exploration	
of	uterus	
Invasive	procedure	
to	control	bleeding,	
fall	in	Hb	≥4	g/L	or	
≥4	units	RBC	
Median	(IQR)	
4.4	(3.7-5.1	 3.3	(2.5–4.2)	
		0.75	(CI	not	
reported)	
P<0.0001	
Cortet
32
	 738	 Diagnosis	of	PPH	 Invasive	procedure	
to	control	bleeding,	
fall	in	Hb	≥4	g/L,	≥4	
units	RBC	or	
admission	too	ITU	
Mean	(SD)	 4.2	(1.2)	 3.4	(0.9)	 0.66		
(0.64-0.68)	
Poujade
55
	 98	 Variable	time	before	
embolisation		
Success	of	
radiological	
embolisation	
Mean	(SD)	 2.9	(1.3)	 1.8	(0.9)	 NR	
Gayat
34
	 257	 Variable	time	before	
procedure	
Invasive	procedure	
to	control	bleeding	
Median	(IQR)	 2.7	(2.1-3.5)	 1.8	(1.1-2.5)	 0.83		
(±0.03)
*	
	
de	Lloyd
33
	 240	 First	clinical	concern	
during	PPH		
≥2500	mL	blood	loss	 Mean	(SD)	 4.4	(1.1)	
	
3.1	(1.0)	 0.85		
(0.78-0.93)	
Collins
14
	 346	 1000-1500	mL	blood	
loss	
Transfusion	of	≥8	
units	allogeneic	
blood	products	
Median	(IQR)	 3.9	(3.2-4.5)	 2.1	(1.8-3.4)	 0.82		
(0.72-0.92)	
Simon
35
	 797	 Before	bleeding	
started	
PPH	requiring	
manual	uterine	
exploration,	RBC	
transfusion	or	fall	in	
Hb	≥2	g/L	
Mean	(SD)	 4.9	(1.0)	 4.3	(1.3)	 NR	
	
Studies	are	shown	which	investigated	the	association	of	Clauss	fibrinogen,	taken	early	during	a	
postpartum	haemorrhage	or	before	bleeding	started,	with	progression	of	bleeding.	Variable	study	
designs	were	employed	but	in	all	cases	a	low	Clauss	fibrinogen	was	associated	with	a	statistically	
significantly	increased	risk	of	progression.	This	demonstrates	that	fibrinogen	level	is	a	useful	
biomarker	for	predicting	progression	of	postpartum	haemorrhage,	however,	do	the	time	required	to	
obtain	a	result	it’s	clinical	utility	is	limited.	NR	not	reported,	CI	confidence	interval,	ROC	receiver	
operating	characteristics	curve,	IQR	inter-quartile	range	and	SD	standard	deviation.	*,	in	this	study	
the	ROC	refers	to	a	composite	predictive	tool	combining	fibrinogen	<	2g/l,	abnormal	placental	
implantation,	PT	ratio	<50%,	heart	rate	>115	beats	per	minute,	troponin	raised.		
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Legends	for	figures		
	
Figure	1:	Study	design	for	OBS-1	
Figure	2:		
The	proportion	of	women	progressing	to	>2500	mL	blood	loss	(red),	red	blood	cell	transfusion	(dark	
blue),	at	least	4	units	red	blood	cell	transfusion	(light	blue)	or	an	invasive	procedure	to	control	the		
bleed	(green)	dependent	on	Clauss	fibrinogen	(Fig	2a)	or	Fibtem	A5	(Fig	2b)	taken	at	1000-1500	
blood	loss	is	shown.		Data	are	derived	from	the	OBS1	study.	
	
Figure	3:	Rotem	guided	blood	product	algorithms	
Figure	2a	show	the	study	design	and	blood	product	algorithm	used	for	women	recruited	into	OBS-2.	
Figure	2b	shows	the	blood	product	algorithm	used	for	women	who	were	not	enrolled.		
	
Figure	4:	Changes	in	transfusion	practice	across	time	in	Cardiff	
Figure	4a	shows	the	number	of	units	of	red	blood	cells	(RBC)	(grey)	and	fresh	frozen	plasma	(FFP)	
(black)	transfused	for	each	year	between	2010	and	2017.	The	OBS2	study	was	associated	with	a	
reduction	in	RBC	and	FFP	transfusion	which	increased	after	the	study	finished	and	fell	again	once	
OBS	Cymru	was	initiated.	Figure	4b	shows	data	for	the	number	of	women	who	received	at	least	5	
units	of	RBC,	representing	a	subgroup	of	very	severe	postpartum	haemorrhage.	A	similar	temporal	
trend	was	observed.		
	
Figure	5:	OBS	Cyrmu	blood	product	algorithm.		
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